These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19385713)

  • 1. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
    Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
    Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
    Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study.
    Venkatakrishnan K; Rader M; Ramanathan RK; Ramalingam S; Chen E; Riordan W; Trepicchio W; Cooper M; Karol M; von Moltke L; Neuwirth R; Egorin M; Chatta G
    Clin Ther; 2009; 31 Pt 2():2444-58. PubMed ID: 20110052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
    Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
    Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib for the treatment of non-Hodgkin's lymphoma.
    Bose P; Batalo MS; Holkova B; Grant S
    Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
    Reece DE; Sullivan D; Lonial S; Mohrbacher AF; Chatta G; Shustik C; Burris H; Venkatakrishnan K; Neuwirth R; Riordan WJ; Karol M; von Moltke LL; Acharya M; Zannikos P; Keith Stewart A
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):57-67. PubMed ID: 20306195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
    Ogawa Y; Tobinai K; Ogura M; Ando K; Tsuchiya T; Kobayashi Y; Watanabe T; Maruyama D; Morishima Y; Kagami Y; Taji H; Minami H; Itoh K; Nakata M; Hotta T
    Cancer Sci; 2008 Jan; 99(1):140-4. PubMed ID: 17970782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
    Fang AF; Damle BD; LaBadie RR; Crownover PH; Hewlett D; Glue PW
    Pharmacotherapy; 2008 Jan; 28(1):42-50. PubMed ID: 18154473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
    Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
    J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
    Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
    Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.